Immunohistochemistry profiles of breast ductal carcinoma: Factor analysis of digital image analysis data

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Laurinavicius, Arvydas ^a   Laurinaviciene, Aida ^a   Ostapenko, Valerijus ^a   Dasevicius, Darius ^a   Jarmalaite, Sonata ^a   Lazutka, Juozas ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Androgen receptors; Breast cancer; Digital pathology; Estrogen receptors; Hypoxia inducible factor 1 ; Immunohistochemistry; Progesteron receptors; Special at rich sequence binding protein 1

Indexed keywords

TUMOR MARKER;

ALGORITHM; ARTICLE; BREAST TUMOR; CANCER GRADING; CANCER STAGING; COMPUTER ASSISTED DIAGNOSIS; FACTORIAL ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; TISSUE MICROARRAY;

ALGORITHMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859364860     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-27     Document Type: Article

References (45)

1. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2011, 9(1):48-57. 10.1038/nrclinonc.2011.178, 22143140.
2. Rakha EA, Ellis IO. Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol 2011, 18(4):255-267. 10.1097/PAP.0b013e318220f5d1, 21654357.
3. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010, 12(4):207. 2949637, 20804570.
4. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22(8):1736-1747. 10.1093/annonc/mdr304, 3144634, 21709140.
5. Kaufmann M, Pusztai L. Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel. Cancer 2011, 117(8):1575-1582. 10.1002/cncr.25660, 21472705.
6. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010, 134(6):907-922. 3073033, 20524868.
7. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131(1):18-43.
8. Tadrous PJ. On the concept of objectivity in digital image analysis in pathology. Pathology 2010, 42(3):207-211. 10.3109/00313021003641758, 20350211.
9. Laurinavicius A, Laurinaviciene A, Dasevicius D, Elie N, Plancoulaine B, Bor C, Herlin P. Digital image analysis in pathology: benefits and obligation. Anal Cell Pathol (Amst) 2012, 35(2):75-78.
10. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010, 120(2):293-308. 10.1007/s10549-010-0746-x, 20107892.
11. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010, 7(5):e1000279. 10.1371/journal.pmed.1000279, 2876119, 20520800.
12. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011, 29(32):4273-4278. 10.1200/JCO.2010.31.2835, 21990413.
13. Madabhushi A, Agner S, Basavanhally A, Doyle S, Lee G. Computer-aided prognosis: predicting patient and disease outcome via quantitative fusion of multi-scale, multi-modal data. Comput Med Imaging Graph 2011, 35(7-8):506-514. 10.1016/j.compmedimag.2011.01.008, 21333490.
14. Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, Pharoah PD, Caldas C. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol 2012, 226(1):97-107. 10.1002/path.2976, 21953021.
15. Soria D, Garibaldi JM, Ambrogi F, Green AR, Powe D, Rakha E, Macmillan RD, Blamey RW, Ball G, Lisboa PJ, et al. A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Comput Biol Med 2010, 40(3):318-330. 10.1016/j.compbiomed.2010.01.003, 20106472.
16. Ismail K. Unravelling factor analysis. Evid Based Ment Health 2008, 11(4):99-102. 10.1136/ebmh.11.4.99, 18952952.
17. Laurinaviciene A, Dasevicius D, Ostapenko V, Jarmalaite S, Lazutka J, Laurinavicius A. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays. Diagn Pathol 2011, 6(1):87. 10.1186/1746-1596-6-87, 3191356, 21943197.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
19. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010, 103(5):668-675. 10.1038/sj.bjc.6605736, 2938244, 20664598.
20. Abdel-Fatah TM, Powe DG, Ball G, Lopez-Garcia MA, Habashy HO, Green AR, Reis-Filho JS, Ellis IO. Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J Pathol 2010, 222(4):388-399. 10.1002/path.2775, 20922713.
21. Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008, 8:153. 10.1186/1471-2407-8-153, 2430210, 18510726.
22. Kallel-Bayoudh I, Hassen HB, Khabir A, Boujelbene N, Daoud J, Frikha M, Sallemi-Boudawara T, Aifa S, Rebai A. Bcl-2 expression and triple negative profile in breast carcinoma. Med Oncol 2011, 28(Suppl 1):S55-61.
23. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 2011, 127(3):591-599. 10.1007/s10549-010-1028-3, 20623333.
24. Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, Bragantini E, Morelli L, Cuorvo LV, Ferro A, et al. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol 2011, 6(Suppl 1):S7. 10.1186/1746-1596-6-S1-S7, 3073225, 21489202.
25. Elzagheid A, Kuopio T, Pyrhonen S, Collan Y. Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?. Diagn Pathol 2006, 1:41. 10.1186/1746-1596-1-41, 1654187, 17092354.
26. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008, 452(7184):187-193. 10.1038/nature06781, 18337816.
27. Patani N, Jiang W, Mansel R, Newbold R, Mokbel K. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int 2009, 9:18. 10.1186/1475-2867-9-18, 2731048, 19642980.
28. Kohwi-Shigematsu T, Han HJ, Russo J, Kohwi Y. Re: The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst 2010, 102(24):1879-1880. author reply 1880-1871, 10.1093/jnci/djq440, 3001965, 21076049.
29. Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M. The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst 2010, 102(16):1284-1296. 10.1093/jnci/djq243, 20595686.
30. Yamayoshi A, Yasuhara M, Galande S, Kobori A, Murakami A. Decoy-DNA against special AT-rich sequence binding protein 1 inhibits the growth and invasive ability of human breast cancer. Oligonucleotides 2011, 21(2):115-121. 10.1089/oli.2010.0277, 21500976.
31. Hanker LC, Karn T, Mavrova-Risteska L, Ruckhaberle E, Gaetje R, Holtrich U, Kaufmann M, Rody A, Wiegratz I. SATB1 gene expression and breast cancer prognosis. Breast 2011, 20(4):309-313. 10.1016/j.breast.2010.10.002, 20980149.
32. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011, 12(1):9-22. 10.1038/nrn2949, 22169972.
33. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, Iwase H. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 2008, 110(3):465-475. 10.1007/s10549-007-9742-1, 17805961.
34. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97(6):1573-1581. 10.1002/cncr.11246, 12627523.
35. Oliveira-Costa JP, Zanetti JS, Silveira GG, Soave DF, Oliveira LR, Zorgetto VA, Soares FA, Zucoloto S, Ribeiro-Silva A. Differential expression of HIF-1alpha in CD44 + CD24-/low breast ductal carcinomas. Diagn Pathol 2011, 6:73. 10.1186/1746-1596-6-73, 3170242, 21824412.
36. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002, 8(6):1831-1837.
37. Dales JP, Beaufils N, Silvy M, Picard C, Pauly V, Pradel V, Formisano-Treziny C, Bonnier P, Giusiano S, Charpin C, et al. Hypoxia inducible factor 1alpha gene (HIF-1alpha) splice variants: potential prognostic biomarkers in breast cancer. BMC Med 2010, 8:44. 10.1186/1741-7015-8-44, 2917392, 20624301.
38. Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, Westra WH, Argani P. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 2009, 33(2):163-175. 10.1097/PAS.0b013e31817f9790, 2965595, 18936692.
39. Stefansson OA, Jonasson JG, Olafsdottir K, Hilmarsdottir H, Olafsdottir G, Esteller M, Johannsson OT, Eyfjord JE. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics: Official J DNA Methyl Soc 2011, 6(5):638-649.
40. Stefansson OA, Jonasson JG, Olafsdottir K, Bjarnason H, Th Johannsson O, Bodvarsdottir SK, Valgeirsdottir S, Eyfjord JE. Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression. Breast Cancer Res 2011, 13(5):R95. 10.1186/bcr3020, 3262207, 21958427.
41. Karray-Chouayekh S, Baccouche S, Khabir A, Sellami-Boudawara T, Daoud J, Frikha M, Jlidi R, Gargouri A, Mokdad-Gargouri R. Prognostic significance of p16INK4a/p53 in Tunisian patients with breast carcinoma. Acta Histochem 2011, 113(5):508-513. 10.1016/j.acthis.2010.05.002, 20598349.
42. Arima Y, Hayashi N, Hayashi H, Sasaki M, Kai K, Sugihara E, Abe E, Yoshida A, Mikami S, Nakamura S, et al. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer 2011,
43. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109(1):25-32. 10.1002/cncr.22381, 17146782.
44. Tang D, Xu S, Zhang Q, Zhao W. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol 2011,
45. He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 2011,